hVIVO Paid €25,000 for a €10 Million Business. The Real Price Comes Later.

hVIVO, the London-listed drug-testing company best known for human challenge trials — deliberately giving healthy volunteers a virus so drugmakers can test a medicine in weeks instead of years — just announced it is buying CRS Berlin, a 32-bed clinic in Germany that runs early-stage trials in dermatology and women's health. The upfront price: €25,000. The clinic did €10 million of revenue last year and is carrying a €10 million orderbook. Which raises a question.

What did hVIVO actually pay?

The real price is a three-year revenue royalty. hVIVO will pay 18% of everything the clinic bills in each of the three years ending December 31, 2028, subject to minimum revenue thresholds, and it expects those payments to total about €6 million gross. It also expects to knock off roughly €2 million of that by absorbing pension obligations tied to the business. Expected net price to the seller: about €4 million, nearly all of it paid after the deal closes, out of the clinic's own future revenue. Yamin "Mo" Khan, hVIVO's CEO, called the structure "self-funding." That is the deal in one word.

Why the cleverness? A year and a half ago, hVIVO did not need it. The company ended 2024 with record revenue of £62.7 million and £44.2 million of cash. In January 2025 it bought two other German clinics — CRS Mannheim and CRS Kiel, the siblings of the Berlin site — for €10 million in cash, added a £3.2 million lab-storage business, and projected 2025 revenue of £73 million. Then the challenge-trial business got cancelled on it. Clients pulled work, and the year came in at £46.8 million of revenue, adjusted EBITDA of £1.4 million (down from £16.4 million), and cash of £14.3 million. By June 2026 the cash balance was about £13 million. An acquisition paid out of future revenue is what a balance sheet like that demands. Last time: cash upfront. This time: €25,000 and a payment stream tied to the clinic's own receipts.

It also helps that hVIVO is not buying a stranger. When it bought Mannheim and Kiel, Berlin stayed behind as the group's "preferred partner", and the relationship had already eaten most of the way toward ownership: shared recruitment, quality, sales and IT processes, and roughly half of Berlin's proposals already being submitted jointly with Mannheim. So this deal is a classification change as much as a new capability — a contractor that already ran inside hVIVO's workflows is being promoted to wholly owned subsidiary. Contract catching up with operations.

The earnout mechanics are where the incentives live, and they deserve a careful read. The 18% is a cut of revenue, not profit. That distinction is the whole game: the clinic earned only €0.3 million of EBITDA on that €10 million of revenue, so 18% of the top line — about €1.8 million a year — is more than six times the profit the business currently makes. A seller paid 18% of everything booked has every reason to fill beds and sign trials, and not much reason to watch costs; hVIVO keeps whatever margin emerges and carries all the cost risk. Management calls the deal "immediately earnings accretive", and that claim only holds together if the combined group runs the clinic at far better than the 3% margin it produced standalone — or if part of the earnout is simply money hVIVO was already paying Berlin as its preferred partner, reclassified from expense to price. The margin lift is the number that determines whether this deal pays, not the €25,000.

The minimum revenue thresholds are the buyer's protection, and they are also why the structure reads as a shared bet. Earnouts exist in deal-making precisely to bridge the gap when buyer and seller disagree about what a business is worth: rather than fix a price today, the seller takes its share out of future revenue. Here the seller gets the big payday only if revenue grows — the clinic's average annual revenue needs to run about 10% above today's level just to reach that expected €6 million — and the buyer pays nothing for growth that does not arrive. That is the closest thing to a vote of confidence a deal like this can carry.

The €2 million pension deduction is plumbing that explains why the €6 million headline and the €4 million check are different numbers: hVIVO is taking the retirement liabilities onto its own books and deducting them from what it owes the seller, which puts the previous owner partway toward funding them out of sale proceeds. "The price" in any acquisition is what it is net of what you are assuming.

What changes for hVIVO as an investment? First, scale. Berlin's €10 million of revenue — roughly £8 million at current exchange rates — is about a sixth of hVIVO's £46.8 million of 2025 revenue, and its orderbook becomes hVIVO's own, on top of a group orderbook that had already more than doubled, to £65 million, by July. For a company worth roughly £45 million, that is a meaningful share of the top line. Second, diversification. hVIVO's core business is infectious-disease and respiratory challenge trials, a single-therapeutic-area dependence that hurt it badly in 2025. Dermatology and women's health are different, large, growing markets — hVIVO cites a US$6.1 billion dermatology CRO market heading to US$9.7 billion by 2034 and a US$9.9 billion women's health CRO market heading to US$22.3 billion by 2036. Third, it preserves cash: €25,000 out the door, the rest paid from the clinic's own revenue.

The caveats are structural. The deal does nothing by itself to repair hVIVO's earnings power — paying 18% of a thin-margin business's top line to the seller for three years is a real cash drain, and the accretion story depends on integration margins the clinic has never demonstrated on its own. And hVIVO's M&A-era forecasts have a recent record of overpromising: the £73 million 2025 outlook became £46.8 million of actual revenue. But the earnout structure is disciplined in one specific sense: hVIVO pays for growth only if it materializes, and it is buying a platform it had already been running in miniature. A low-cash way to buy scale, diversification, and a completed German network. Whether it is a low-cash way to buy profit is what the next few filings will decide.